The US Centres for Disease Control and Prevention (CDC) confirmed on Friday that an American citizen working for a humanitarian organization in the Democratic Republic of Congo has tested positive for the Ebola virus. The CDC is collaborating with the patient's employer, US agencies, Congolese health authorities, and local partners to trace close contacts and prevent further transmission. No additional details about the individual were disclosed.
Fastest-Growing Ebola Outbreak on Record
Earlier this week, the Africa Centres for Disease Control and Prevention reported that this outbreak is the fastest-growing Ebola outbreak ever recorded on the continent. As of the latest data, there are 1,830 confirmed cases in Congo, including 648 deaths. Cases have also been confirmed in neighboring Uganda, raising regional concerns.
The outbreak was officially declared by Congolese authorities on May 15, after the disease had been spreading undetected for weeks, according to the World Health Organization. The virus responsible is the rare Bundibugyo strain, for which no approved vaccine or treatment currently exists.
Previous US Case and Treatment Challenges
In the first week of the outbreak, an American doctor working in Congo also tested positive for Ebola and was transferred to Germany for treatment. Initially, Trump administration officials had announced plans to send Americans exposed to Ebola abroad to a new facility in Kenya, rather than repatriating them to the United States. However, that project was suspended following a court order in Kenya.
Obstacles to Containment
Efforts to contain the virus have been hampered by a funding gap, repeated attacks on health centers, and ongoing conflict in eastern Congo, which is the epicenter of the outbreak. Last week, clinical trials for potential treatments began after researchers launched a highly anticipated study aimed at finding effective therapies against the Bundibugyo virus.
The CDC emphasized its commitment to working with all partners to stop the spread of the virus, but the combination of a rare pathogen, logistical hurdles, and security challenges makes this outbreak particularly difficult to control.
